AM-Pharma B.V.: Treating sepsis associated acute kidney injury (AKI) with proprietary recombinant alkaline phosphatase (recAP). Results from Ph 2 trial in 300+ pts, demonstrated relative improvement of 40%+ OS in recAP group. Initiating Ph 3 in Q3 2020 – interim look (n=400) exp Q3 2021 (P endpoint: Day 28 all-cause mortality).
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Pre-Clinical Stage
Disease Space
Anti-inflammatory
Industry
Biotechnology, Pharmaceuticals
Listing
Private
Website:
Profiles:
Address:
Stadsplateau 6
3521
Utrecht
Netherlands

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Summer 2020 NYC Private Company Showcase

New York, NY, August 10, 2020